ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Atara Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.96−0.22 (-2.40%)
Close on Oct 19, 2026
- Market cap
- $134.70M
- P/E (TTM)
- 3.5
- Dividend yield
- –
Atara Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $89.94M | $197.05M |
| Enterprise Value | $80.04M | $106.56M |
| PS Ratio | 14.52 | 3.93 |
Enterprise value
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| EV / Sales | 12.92 | 2.69 |
Income (trailing twelve months)
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Revenue | $6.19M | $57.94M |
| Operating Income | -$14.23M | -$21.44M |
| Pretax Income | -$16.66M | -$14.45M |
| Net Income | -$16.69M | -$22.46M |
| EBITDA | -$14.10M | -$16.91M |
Margins
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Operating Margin | -229.7% | -44.5% |
| Pretax Margin | -269.0% | -13.0% |
| Profit Margin | -269.4% | -39.2% |
| EBITDA Margin | -227.6% | -31.3% |
Returns
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -57.6% | -41.0% |
| Return on Capital Employed (ROCE) | -100.3% | -37.8% |
Growth
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -96.7% | 6.01% |
| Net Income Growth (YoY) | -388.0% | -37.7% |
| Revenue Growth (3Y CAGR) | 23.9% | 2.25% |
Balance sheet
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $9.90M | $62.42M |
| Net Cash (Debt) | $9.90M | $15.68M |
| Net Cash Per Share | $0.99 | $0.65 |
| Equity (Book Value) | -$37.00M | $48.79M |
| Book Value Per Share | -$3.69 | $1.36 |
| Tangible Book Value | -$37.00M | $23.06M |
| Working Capital | $6.68M | $75.77M |
Financial position
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.98 | 3.30 |
| Quick Ratio | 1.49 | 2.39 |
| Interest Coverage | -5.04 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$21.90M | -$12.35M |
Efficiency
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.21 | 0.38 |
| Revenue Per Employee | $442.43K | $398.96K |
| Profits Per Employee | -$1.19M | -$732.08K |
| Employee Count | 14 | 73 |
Dividends and yields
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | -18.6% | -21.2% |
| Buyback Yield | -10.3% | -0.58% |
| Shareholder Yield | -10.3% | 0.00% |
Shares
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 10,037,700 | 59,128,900 |
| Shares Change (YoY) | 36.9% | 11.1% |
| Shares Change (QoQ) | 10.9% | 0.54% |
| Float | 4,471,430 | 48,744,500 |
| Shares Held by Insiders | 55.5% | 11.8% |
| Shares Held by Institutions | 44.5% | 59.4% |
Taxes
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Income Tax | $29.00K | $91.50K |
Scores
| Measure | Atara Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -135.86 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Atara Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.